Evidence map›Paper›PMID 25861316›Full record

ArticleHepatitis monthly2015

Optimization of Three Dimensional Culturing of the HepG2 Cell Line in Fibrin Scaffold.

Mehrzad Banihashemi, Milad Mohkam, Azam Safari, Navid Nezafat, Manica Negahdaripour, Fatemeh Mohammadi, Sedigheh Kianpour, Younes Ghasemi

Abstract read
In one paragraph

Article in Hepatitis monthly, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Bone Tissue Engineering in the Treatment of Bone Defects.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mehrzad BanihashemiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Milad MohkamPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran ; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Azam SafariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Navid NezafatPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Manica NegahdaripourPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Fatemeh MohammadiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran ; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Sedigheh KianpourPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran ; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Younes GhasemiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran ; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA potential treatment for healing hepatic tissue is delivering isolated hepatic cells to the site of injury to promote hepatic cells formation. In this technology, providing an appropriate injectable system for delivery of hepatic cells is an important issue. In this regard, fibrin scaffolds were designed with many advantages over other scaffolds like cell delivery vehicles for biodegradation, biocompatibility and hemostasis.

objectivesThe aim of this study was to determine suitable cell culture circumstances for HepG2 cell proliferation and differentiation in 3D fibrin scaffolds by evaluating Ca(2+) concentrations, cell numbers, various ratios of plasma/RPMI 1640 and thickness of fibrin scaffold. MATERIALS AND

methodsIn a one-stage experimental design, Box-Behnken design strategy was performed by Minitab 15 software (version 15, Minitab. State College, PA) with three factors at three levels (low, medium and high) and 27 runs for identification of the effects of ratio of plasma/RPMI 1640, Ca(2+) concentration and thickness on the formation of fibrin gel scaffold and 3D HepG2 culture.

resultsThe optimal concentrations for fibrin scaffold fabrication were achieved by adding 0.15 mol CaCl2 (50 µL) and 1 × 10(5) cells to 1:4 of plasma/RPMI 1640 ratio (500 µL with 2.3 mm thickness per well).

conclusionsOur approach provided easy handle method using inexpensive materials like human plasma instead of purified fibrinogen to fabricate fibrin scaffold.

Indexed as

Experimental DesignFibrinHepG2 CellsPlasma

Identifiers

PMID25861316
PMCPMC4385269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.